Why is "Beta thalassemia" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-26 00:53:26
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Beta_thalassemia entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-26 and was most recently seen on 2026-03-26.
Wikipedia Overview
Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severe anemia individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Gene Therapy Cures Soccer-Loving Boy of Beta Thalassemia - Stanford Children's Health
-
How to Fight Fatigue From Beta Thalassemia - HealthCentral
-
Compound Heterozygous Sickle Cell-Beta Thalassemia Presenting As Chronic Hemolytic Anemia With Microcytosis and Prominent Left Ventricular Trabeculation: A Case Report - Cureus
-
Base Editing Shows Early Promise for Treating Beta Thalassemia - Inside Precision Medicine
-
FDA Expands Use of Gene Therapy for Treatment of Patients Ages 2+ with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia - Children's Hospital of Philadelphia
-
Book’s story of living with Beta Thalassemia - Bristol Myers Squibb
-
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia - Business Wire
-
FDA Approves Mitapivat for Transfusion-Dependent and Non-Transfusion-Dependent Alpha- and Beta-Thalassemia - HCPLive
-
Beta Thalassemia Treatment Market Size, Growth Forecasts 2035 - Research Nester
-
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia - Genetic Engineering and Biotechnology News
-
Ultime Novità sulla Ricerca Promossa da Telethon - fondazionetelethon.it
-
FDA Expands Casgevy for Children 2+ with Sickle Cell Disease - respiratory-therapy.com
-
“I Can’t Tell You How Many Times People Said ‘It Will Never Work’”: The Pioneers Of Gene Therapy Honored In Two Of This Year’s Breakthrough Prizes - IFLScience
-
Stuart Orkin Awarded the 2026 Breakthrough Prize - HHMI
-
Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia - News-Medical
-
FDA Approves Mitapivat as First Oral Treatment for Anemia in Adults With Alpha- or Beta-Thalassemia - consultant360.com
-
Impact of Beta-Thalassemia Trait on Clinical Outcomes and Treatment Response in Chronic Myeloid Leukemia - Cureus
-
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany - Business Wire
-
Challenges and opportunities in delivering gene therapies for sickle cell disease and beta thalassemia - News-Medical
-
Compound Heterozygous Hemoglobin E-Beta (HbE-β)-Thalassemia Presenting With Chipmunk or Rodent Facies, and a Severe Thalassemia Major Phenotype - Cureus
-
A Case Series on Beta Thalassemia Major With Secondary Diabetes Mellitus Due to Iron Overload and Other Complications - Cureus
-
Gene therapy for sickle cell and β-thalassemia works by disrupting three-dimensional genome structure - St. Jude Children's Research Hospital
-
Sickle cell and beta thalassemia: what are the treatment options and challenges? - UK Parliament
-
Living stronger with beta thalassemia through care and innovation - Bristol Myers Squibb
-
12-year-old Greenwood girl first to receive new gene therapy for rare blood disorder in Indiana - WTHR
-
FDA Approves Mitapivat for Thalassemia-Related Anemia - MedPage Today
-
Beta Thalassemia Testing Market Size, Share | CAGR Of 8.3% - Market.us
-
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025 - Managed Healthcare Executive
-
Eduardo’s inspiring journey of hope and support with beta thalassemia - Bristol Myers Squibb
-
First gene editing therapy to treat beta thalassemia and severe sickle cell disease - European Medicines Agency (EMA)
-
FDA Approves First Potentially Curative Gene Therapy for Beta Thalassemia - Children's Hospital of Philadelphia
-
Russia's Circle of Kindness Backs Reblozyl for Children With Beta-Thalassemia - NAVLIN DAILY
-
Chinese trial backs base-editing drug for thalassaemia - pharmaphorum
-
FDA clears first CRISPR treatment for a second disease, beta thalassemia - cnn.com
-
Dana-Farber Treats First Patient with Approved Gene Therapy for Beta Thalassemia - Dana-Farber Cancer Institute
-
USFDA Approves Agios Pharma's Aqvesme for Alpha, Beta Thalassemia Anemia - Medical Dialogues
-
Genetic Study for Identifying Beta Thalassemia Trait in Relatives of Children with Beta Thalassemia Major - Cureus
-
How I explain sickle beta-zero thalassemia to others - sicklecellanemianews.com
-
FDA approves Casgevy gene therapy for children 2+ with sickle cell disease and beta thalassemia - Pluang
-
FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia - Indian Pharma Post
-
Gene Therapy for Beta Thalassemia: Rahemeen’s Story - Children's Hospital of Philadelphia
-
Zydus gets USFDA's orphan drug designation for beta-thalassemia product - pharma.economictimes.indiatimes.com
-
Assessment of health-related quality of life in transfusion dependent beta thalassemia - Nature
-
Press Release Service: Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - CRISPR Medicine News
-
Beta-Thalassemia in Adulthood Previously Suspected as Treatment-Resistant Iron Deficiency Anemia: A Case Report - Cureus
-
Two New Cures for Transfusion-Dependent Beta Thalassemia - HealthCentral
-
Beta-thalassemia disease prevention: genetic medicine applied - National Institutes of Health (NIH) | (.gov)
-
University of Health Sciences team makes headway against thalassemia in Punjab - Dawn
-
Yuetong’s Journey Battling Beta Thalassemia While Pursuing His Passion - Bristol Myers Squibb
-
Major study to track impacts of childhood blood disorders - leeds.ac.uk
-
From Frequent Transfusions to a Cure for Beta Thalassemia - Stanford Children's Health
-
Gene therapy a viable cure for beta thalassemia, study says - Nature
-
Arterial Leg Ulcerations Associated With Beta-Thalassemia - hmpgloballearningnetwork.com
-
Cardiovascular Effects of Splenomegaly and Splenectomy in Beta-Thalassemia Major - Cureus
-
Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia - Fierce Pharma
-
LLUH first in Southern California to offer beta thalassemia gene therapy - Loma Linda University
-
Personal Story: Radhika Sawh - Centers for Disease Control and Prevention | CDC (.gov)
-
Gene Therapy Promotes Transfusion Independence for Severe Beta-Thalassemia - news.feinberg.northwestern.edu
-
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia - BioPharma Dive
-
FDA expands approval of CRISPR-based medicine to treat beta thalassemia - STAT
-
Patients With Beta-Thalassemia Receiving Therapy May Suffer From Growth Issues - Hematology Advisor
-
Zydus Secures USFDA Orphan Drug Designation For Desidustat In Beta-Thalassemia - BW Healthcare World
-
SurvivorNet: Perlmutter Cancer Center Hematologist–Oncologist Discusses New Treatment for Beta Thalassemia - NYU Langone Health
-
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia - BioPharma Dive
-
Bleeding and Thrombotic Risks in Young Patients With Beta-Thalassemia Major - Hematology Advisor
-
A comprehensive case study of deep learning on the detection of alpha thalassemia and beta thalassemia using public and private datasets - Nature
-
Reduced Exercise Capacity Associated With Cardiac Iron Overload in Beta-Thalassemia Major - Hematology Advisor
-
Children’s Hospital of Philadelphia’s First FDA Approved Gene Therapy Patient for Severe Beta Thalassemia Celebrates Two-Year Treatment Anniversary - Children's Hospital of Philadelphia
-
Reducing Transfusion Burden and Addressing Unmet Needs in Beta Thalassemia - Hematology Advisor
-
Cell therapy weekly: FDA authorizes CASGEVY for beta thalassemia - RegMedNet
-
You Make the Call: How would you manage a patient with a history of beta thalassemia major and pancytopenia who requires frequent blood transfusions? | ASH Clinical News | American Society of Hematology - ashpublications.org
-
Study of Thyroid Function in Children With Beta-Thalassemia Major - Cureus
-
Overview of Beta Thalassemia - OncLive
-
The genetic architecture of the β-globin chain in individuals with and without sickle cell disease in Nigeria: A case for beta thalassemia? - medRxiv
-
Safety of Luspatercept in Pediatric Beta-Thalassemia Comparable With Adults - DocWireNews
-
Interim Analysis Shows Exa-Cel Leads to Transfusion Independence in Beta-Thalassemia - DocWireNews
-
United Kingdom approves first-ever CRISPR treatment, a cure for sickle cell disease and beta thalassemia - Science | AAAS
-
Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News
-
Arrhythmias During Pregnancy: Ventricular Tachycardia in the Setting of Maternal Beta Thalassemia Minor - Cureus
-
Incidental Diagnosis of Adult Beta-Thalassemia With Point-of-Care Ultrasound in the Emergency Department: A Case Report - Cureus
-
Genetic Manipulation Strategies for β-Thalassemia: A Review - Frontiers
-
Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder - STAT
-
What it means to be a designated treatment center for beta thalassemia - Children's National
-
Beta Thalassemia Market Size to Reach USD 822.5 Million by 2034, Impelled by Novel Treatment Methods - BioSpace
-
CRISPR Clinical Trial Update – Beta Thalassemia - CRISPR Medicine News
-
Prevalence and Clinical Presentation of Beta Thalassemia - HCPLive
-
Gene therapy a potential ‘functional cure’ for sickle cell disease, beta thalassemia - Healio
-
Personal Story: Courtney - Centers for Disease Control and Prevention | CDC (.gov)
-
Tina's journey with beta thalassemia: From patient to clinical trial participant - Bristol Myers Squibb
-
FDA Approves Vertex, CRISPR’s Casgevy to Treat Beta Thalassemia - BioSpace
-
The Cost and Safety of Gene Therapy in Beta-Thalassemia - OncLive
-
As Survival Increases in Beta Thalassemia, Renal Complications Emerge - Hematology Advisor
-
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia - NEJM
-
Lipid Profiles in Beta-Thalassemia With IVS Mutations and Hydroxyurea Therapy - Hematology Advisor
-
Is the cure for genetic beta thalassemia finally within reach? - Medical Xpress
-
Association between genotype and disease complications in Egyptian patients with beta thalassemia: A Cross-sectional study - Nature
-
Hydroxyurea Plus Thalidomide Shows Promising Results in Pediatric Patients With Beta-Thalassemia - Hematology Advisor
-
Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype - Nature
-
FDA Approves Single-Dose Betibeglogene Autotemcel for Patients With Beta-Thalassemia Who Require RBC Transfusions - Oncology Nursing News
-
Psychological Models May Aid in Improving ICT Adherence in Beta-Thalassemia - Hematology Advisor
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.